No Data
No Data
Northland Securities Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $12.5
TriSalus Life Sciences Says Prelim. Q1 Results Show ~$9.2M In Revenue, Driven By TriNav Infusion System
TriSalus Life Sciences Announces $22M Private Placement Of 5.5M Shares Of Common Stock At A Price Of $4/Share
Trisalus Life Sciences Secures $22M In Securities Purchase Agreement For Common Stock
TriSalus Life Sciences: Expects Placement to Fund Business to Profitability >TLSI
Express News | TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results